This oral drug could reduce COVID-19 death risk by 55%

Scientists from Veru Inc., an oncology biopharmaceutical company, found a novel COVID-19 drug reduces deaths by 55% in patients at high risk for Acute Respiratory Distress Syndrome (ARDS).

In the study, the team tested the drug in approximately 210 people with moderate to severe COVID-19 who were at high risk for ARDS and death.

Patients were assigned to the sabizabulin treatment group versus placebo.

Patients in both treatment groups were allowed to receive standard of care including remdesivir, dexamethasone, anti-IL6 receptor antibodies, and JAK inhibitors.